Pfizer Inc. (NYSE:PFE) Position Lifted by Harbor Advisors LLC

Harbor Advisors LLC raised its stake in shares of Pfizer Inc. (NYSE:PFE) by 68.6% during the fourth quarter, HoldingsChannel reports. The fund owned 31,962 shares of the biopharmaceutical company’s stock after acquiring an additional 13,000 shares during the quarter. Harbor Advisors LLC’s holdings in Pfizer were worth $920,000 as of its most recent SEC filing.

A number of other large investors have also recently added to or reduced their stakes in PFE. Briaud Financial Planning Inc bought a new position in shares of Pfizer in the 3rd quarter worth about $30,000. GoalVest Advisory LLC increased its holdings in shares of Pfizer by 304.9% in the 4th quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock worth $31,000 after acquiring an additional 811 shares during the period. Mizuho Securities Co. Ltd. acquired a new stake in shares of Pfizer in the 3rd quarter worth about $34,000. VisionPoint Advisory Group LLC increased its holdings in shares of Pfizer by 52,350.0% in the 3rd quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock worth $35,000 after acquiring an additional 1,047 shares during the period. Finally, Tennessee Valley Asset Management Partners acquired a new stake in shares of Pfizer in the 4th quarter worth about $36,000. 68.36% of the stock is currently owned by institutional investors.

Pfizer Trading Up 0.2 %

Shares of PFE traded up $0.06 during midday trading on Tuesday, hitting $26.32. The stock had a trading volume of 23,845,774 shares, compared to its average volume of 42,104,582. Pfizer Inc. has a fifty-two week low of $25.23 and a fifty-two week high of $40.37. The business has a 50-day simple moving average of $27.08 and a two-hundred day simple moving average of $28.56. The firm has a market cap of $149.04 billion, a P/E ratio of 73.11, a price-to-earnings-growth ratio of 1.17 and a beta of 0.61. The company has a current ratio of 0.91, a quick ratio of 0.69 and a debt-to-equity ratio of 0.69.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 EPS for the quarter, topping the consensus estimate of ($0.19) by $0.29. The business had revenue of $14.25 billion during the quarter, compared to analysts’ expectations of $14.37 billion. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. The firm’s quarterly revenue was down 41.3% compared to the same quarter last year. During the same period last year, the company posted $1.14 earnings per share. As a group, equities analysts forecast that Pfizer Inc. will post 2.24 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on PFE. Guggenheim began coverage on shares of Pfizer in a report on Friday, February 23rd. They issued a “buy” rating and a $36.00 price objective on the stock. TD Cowen cut shares of Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price objective on the stock. in a report on Thursday, January 4th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $45.00 price objective on shares of Pfizer in a report on Monday, April 15th. Finally, Argus cut shares of Pfizer from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. Eleven analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $36.33.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.